logo

Verastem, Inc. (VSTM)



Trade VSTM now with
  Date
  Headline
3/11/2020 4:10:24 PM Verastem Oncology Q4 Loss/share $0.51 Vs. Loss $0.37 Year Ago
2/28/2020 6:15:28 AM Verastem Oncology Announces New Strategic Direction To Advance Its Clinical Development Programs
2/28/2020 6:04:48 AM Verastem Agrees To Sell About 46.5 Mln Common Shares To Certain Institutional Investors
1/29/2020 7:25:59 AM Verastem Oncology Reports Dosing Of First Patient In CSPC's Chinese Study Evaluating COPIKTRA
1/8/2020 7:08:41 AM Verastem Oncology Announces Global Licensing Deal With Chugai Pharma To Develop RAF/MEK Inhibitor CH5126766
10/23/2019 7:44:00 AM Verastem Oncology Announces COPIKTRA Presentations At Lymphoma & Myeloma 2019 International Congress
10/7/2019 7:03:09 AM Yakult Doses First Patient In Phase 1b Japanese Bridging Study Of COPIKTRA In Patients With R/R CLL/SLL
10/4/2019 7:05:38 AM Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
7/3/2019 7:08:24 AM Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
6/20/2019 7:07:39 AM Verastem Oncology: Robert Forrester To Step Down As President And CEO
2/20/2019 7:17:04 AM Verastem Announces Several Key Appointments To Its Management Team
12/4/2018 7:08:00 AM Verastem Presents Duvelisib Development Program Data At American Society Of Hematology 2018 Annual Meeting
10/9/2018 7:08:39 AM NCCN Adds Verastem Oncology’s COPIKTRA Capsules To Clinical Practice Guidelines In Oncology
10/8/2018 7:12:40 AM NCCN Adds Verastem Oncology’s COPIKTRA Capsules To Clinical Practice Guidelines In Oncology
9/6/2018 7:08:06 AM Verastem Oncology Announces Investigator Sponsored Study On Duvelisib In Combination With Venetoclax
  
 
>